Alderman M H, Madhavan S
Hypertension. 1981 Mar-Apr;3(2):192-7. doi: 10.1161/01.hyp.3.2.192.
The proper management of mild and moderate hypertension remains a matter of considerable professional disagreement. Major clinical and population research has largely been designed to define a level of blood pressure (BP) at which treatment should be initiated. This paper reviews studies of the natural history of hypertension and the findings of intervention trials to determine whether the BP level alone is adequate to identify, diagnose, and predict the future course of hypertensive patients. Observational data suggest that patients defined by mild elevation of BP are a heterogeneous group who do not share a common prognosis. Moreover, intervention trials reveal that not all those at risk of cardiovascular disease will benefit from hypotensive therapy. Thus, BP level alone defines neither the group at risk nor those likely to benefit from BP reduction. It is therefore concluded that the management of each patient with hypertension should be determined on the basis of available clinical, biochemical, and behavioral as well as epidemiological data.
轻度和中度高血压的合理管理仍然是一个存在相当大专业分歧的问题。主要的临床和人群研究大多旨在确定应该开始治疗的血压水平。本文回顾了高血压自然史的研究以及干预试验的结果,以确定仅血压水平是否足以识别、诊断和预测高血压患者的未来病程。观察数据表明,血压轻度升高所定义的患者是一个异质性群体,他们没有共同的预后。此外,干预试验表明,并非所有有心血管疾病风险的人都能从降压治疗中获益。因此,仅血压水平既不能定义有风险的群体,也不能定义可能从降低血压中获益的群体。因此得出结论,每位高血压患者的管理都应基于现有的临床、生化、行为以及流行病学数据来确定。